Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

DDX3 regulates endoplasmic reticulum stress-induced ATF4 expression.

Adjibade P, Grenier St-Sauveur V, Bergeman J, Huot ME, Khandjian EW, Mazroui R.

Sci Rep. 2017 Oct 23;7(1):13832. doi: 10.1038/s41598-017-14262-7.

2.

The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

De Falco V, Carlomagno F, Li HY, Santoro M.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):307-318. doi: 10.1016/j.beem.2017.04.013. Epub 2017 May 10. Review.

PMID:
28911727
3.

KIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub.

Das TK, Cagan RL.

Cell Rep. 2017 Sep 5;20(10):2368-2383. doi: 10.1016/j.celrep.2017.08.037.

4.

Structural Characterization of Maize SIRK1 Kinase Domain Reveals an Unusual Architecture of the Activation Segment.

Aquino B, Couñago RM, Verza N, Ferreira LM, Massirer KB, Gileadi O, Arruda P.

Front Plant Sci. 2017 May 26;8:852. doi: 10.3389/fpls.2017.00852. eCollection 2017.

5.

mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells.

Silvera D, Ernlund A, Arju R, Connolly E, Volta V, Wang J, Schneider RJ.

Mol Cell Biol. 2017 Feb 15;37(5). pii: e00577-16. doi: 10.1128/MCB.00577-16. Print 2017 Mar 1.

6.

Non-clinical studies required for new drug development - Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies.

Andrade EL, Bento AF, Cavalli J, Oliveira SK, Freitas CS, Marcon R, Schwanke RC, Siqueira JM, Calixto JB.

Braz J Med Biol Res. 2016 Oct 24;49(11):e5644. doi: 10.1590/1414-431X20165644. Review.

7.

Polypharmacology in Precision Oncology: Current Applications and Future Prospects.

Antolin AA, Workman P, Mestres J, Al-Lazikani B.

Curr Pharm Des. 2016;22(46):6935-6945. doi: 10.2174/1381612822666160923115828.

8.

Kinase inhibitors as potential agents in the treatment of multiple myeloma.

Abramson HN.

Oncotarget. 2016 Dec 6;7(49):81926-81968. doi: 10.18632/oncotarget.10745. Review.

9.

Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data mining.

Verma N, Rai AK, Kaushik V, Brünnert D, Chahar KR, Pandey J, Goyal P.

Sci Rep. 2016 Sep 22;6:33949. doi: 10.1038/srep33949.

10.

mTOR inhibitors in cancer therapy.

Xie J, Wang X, Proud CG.

F1000Res. 2016 Aug 25;5. pii: F1000 Faculty Rev-2078. doi: 10.12688/f1000research.9207.1. eCollection 2016. Review.

11.

Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design?

Christmann-Franck S, van Westen GJ, Papadatos G, Beltran Escudie F, Roberts A, Overington JP, Domine D.

J Chem Inf Model. 2016 Sep 26;56(9):1654-75. doi: 10.1021/acs.jcim.6b00122. Epub 2016 Aug 11.

12.

Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.

Fraser C, Dawson JC, Dowling R, Houston DR, Weiss JT, Munro AF, Muir M, Harrington L, Webster SP, Frame MC, Brunton VG, Patton EE, Carragher NO, Unciti-Broceta A.

J Med Chem. 2016 May 26;59(10):4697-710. doi: 10.1021/acs.jmedchem.6b00065. Epub 2016 May 4.

13.

Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.

Lee HM, Kim Y.

Schizophr Res Treatment. 2016;2016:6378137. doi: 10.1155/2016/6378137. Epub 2016 Mar 17. Review.

14.

Identification of modulators of autophagic flux in an image-based high content siRNA screen.

Hale CM, Cheng Q, Ortuno D, Huang M, Nojima D, Kassner PD, Wang S, Ollmann MM, Carlisle HJ.

Autophagy. 2016;12(4):713-26. doi: 10.1080/15548627.2016.1147669.

15.

Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders.

Evangelisti C, Cenni V, Lattanzi G.

Br J Clin Pharmacol. 2016 Nov;82(5):1229-1244. doi: 10.1111/bcp.12928. Epub 2016 May 18. Review.

16.

Using hydrogen deuterium exchange mass spectrometry to engineer optimized constructs for crystallization of protein complexes: Case study of PI4KIIIβ with Rab11.

Fowler ML, McPhail JA, Jenkins ML, Masson GR, Rutaganira FU, Shokat KM, Williams RL, Burke JE.

Protein Sci. 2016 Apr;25(4):826-39. doi: 10.1002/pro.2879. Epub 2016 Feb 1.

17.

A convenient four-component one-pot strategy toward the synthesis of pyrazolo[3,4-d]pyrimidines.

Liu M, Li J, Chai H, Zhang K, Yang D, Zhang Q, Shi D.

Beilstein J Org Chem. 2015 Nov 6;11:2125-31. doi: 10.3762/bjoc.11.229. eCollection 2015.

18.

Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.

Kuhlenschmidt TB, Rutaganira FU, Long S, Tang K, Shokat KM, Kuhlenschmidt MS, Sibley LD.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):570-9. doi: 10.1128/AAC.01915-15.

19.

Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.

Alam MM, Lee SC, Jung Y, Yun HJ, Min HY, Lee HJ, Pham PC, Moon J, Kwon DI, Lim B, Suh YG, Lee J, Lee HY.

Oncotarget. 2015 Dec 1;6(38):40598-610. doi: 10.18632/oncotarget.5839.

20.

KLIFS: a structural kinase-ligand interaction database.

Kooistra AJ, Kanev GK, van Linden OP, Leurs R, de Esch IJ, de Graaf C.

Nucleic Acids Res. 2016 Jan 4;44(D1):D365-71. doi: 10.1093/nar/gkv1082. Epub 2015 Oct 22.

Supplemental Content

Support Center